<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Direct-acting antivirals for the treatment of hepatitis C virus infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Direct-acting antivirals for the treatment of hepatitis C virus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Direct-acting antivirals for the treatment of hepatitis C virus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Pockros, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1225365818"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A greater understanding of the hepatitis C virus (HCV) genome and proteins has enabled efforts to improve efficacy and tolerability of HCV treatment. Notably, this has led to the development of multiple direct-acting antivirals (DAAs), which are medications targeted at specific steps within the HCV life cycle  (<a class="graphic graphic_figure graphicRef94365" href="/z/d/graphic/94365.html" rel="external">figure 1</a>). DAAs are molecules that target specific nonstructural proteins of the virus and results in disruption of viral replication and infection. There are four classes of DAAs, which are defined by their mechanism of action and therapeutic target. The four classes are nonstructural proteins 3/4A (NS3/4A) protease inhibitors (PIs), NS5B nucleoside polymerase inhibitors (NPIs), NS5B non-nucleoside polymerase inhibitors (NNPIs), and NS5A inhibitors<sup> </sup>[<a href="#rid1">1</a>].</p><p>This topic reviews the mechanism of action, pharmacology, and spectrum of use of these various DAAs. It focuses on the most common agents used globally for antiviral treatment of HCV infection. However, availability of DAAs varies by location, and in some countries, DAAs not discussed in this topic may be in use. </p><p>Other important issues related to the treatment of chronic HCV infection, including patient evaluation, selection of treatment regimen, and other management issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.) </p><p class="headingAnchor" id="H926852676"><span class="h1">CLASSES OF DIRECT-ACTING ANTIVIRALS</span></p><p class="headingAnchor" id="H1648600930"><span class="h2">Viral life cycle and replication overview</span><span class="headingEndMark"> — </span>The main targets of the direct-acting antiviral (DAA) agents are the HCV-encoded proteins that are vital to the replication of the virus  (<a class="graphic graphic_figure graphicRef94365" href="/z/d/graphic/94365.html" rel="external">figure 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral structure</strong> – The infectious viral structure is comprised of envelope glycoproteins in a lipid bilayer that contain the viral core protein and RNA [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RNA translation and protein processing</strong> – After cell entry, the viral RNA is translated through host machinery into a polyprotein, which is cleaved during and after translation by both host and viral-encoded proteases into 10 mature viral proteins, including a number of nonstructural (NS) proteins. </p><p></p><p class="bulletIndent1">One of the viral proteases involved in this post-translational processing is a heterodimeric complex of the NS3 and NS4A proteins (NS3/NS4A). NS3 possesses the proteolytic activity and NS4 is a membrane protein that acts as a cofactor. (See <a class="local">'NS3/4A protease inhibitors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Synthesis and assembly of viral RNA </strong>– Synthesis of new viral RNA occurs in a highly structured replication complex that consists of NS3, NS4A, NS4B, NS5A, and NS5B. </p><p></p><p class="bulletIndent1">NS5B is an RNA-dependent RNA polymerase that is essential for viral replication. (See <a class="local">'NS5B RNA-dependent RNA polymerase inhibitors'</a> below.)</p><p></p><p class="bulletIndent1">NS5A has a presumptive role in the organization of the replication complex and in regulating replication. It is also involved in assembly of the viral particle that is released from the host cell. (See <a class="local">'NS5A inhibitors'</a> below.)</p><p></p><p>Direct-acting antivirals are inhibitors of the NS3/4A protease, the NS5A protein, and the NS5B polymerase.</p><p class="headingAnchor" id="H1225365824"><span class="h2">NS3/4A protease inhibitors</span><span class="headingEndMark"> — </span>Contemporary NS3/4A protease inhibitors include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glecaprevir</strong> – a potent, pangenotypic protease inhibitor that is only available in combination with the NS5A inhibitor pibrentasvir. (See <a class="local">'Glecaprevir-pibrentasvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voxilaprevir</strong> – a potent, pangenotypic protease inhibitor that is only available in combination with the NS5B inhibitor <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and the NS5A inhibitor velpatasvir. (See <a class="local">'Sofosbuvir-velpatasvir-voxilaprevir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grazoprevir</strong> – a protease inhibitor that is only available in combination with the NS5A inhibitor elbasvir. (See <a class="local">'Elbasvir-grazoprevir'</a> below.)</p><p></p><p>These agents inhibit the NS3/4A serine protease, an enzyme involved in post-translational processing and replication of HCV. Protease inhibitors disrupt HCV by blocking the NS3 catalytic site or the NS3/NS4A interaction<sup> </sup>[<a href="#rid3">3</a>]. In addition to its role in viral processing, the NS3/NS4A protease blocks TRIF-mediated Toll-like receptor signaling and Cardif-mediated retinoic acid–inducible gene 1 (RIG-1) signaling, which result in impaired induction of interferons and blocking viral elimination. Thus, inhibition of the NS3/4A protease could contribute to antiviral activity through two mechanisms.</p><p>Newer-generation protease inhibitors offer several benefits over earlier protease inhibitors, including fewer drug-drug interactions, improved dosing schedules, and less frequent and less severe side effects. Additionally, they have a relatively low barrier to resistance  (<a class="graphic graphic_table graphicRef93884" href="/z/d/graphic/93884.html" rel="external">table 1</a>).</p><p>Telaprevir and boceprevir were the first-generation protease inhibitors as well as the first DAAs available for the treatment of HCV, and they were used in conjunction with peginterferon and <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for the treatment of genotype 1 infection but are no longer used [<a href="#rid4">4,5</a>]. Later-generation protease inhibitors that are not commonly or widely used include paritaprevir and asunaprevir. <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">Simeprevir</a> is another protease inhibitor that is not widely available but may be used in some parts of the world. (See <a class="local">'Simeprevir'</a> below.)</p><p class="headingAnchor" id="H1225365830"><span class="h2">NS5A inhibitors</span><span class="headingEndMark"> — </span>Contemporary NS5A inhibitors include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pibrentasvir</strong> – a pangenotypic NS5A inhibitor pibrentasvir that is only available as a fixed-dose combination with the protease inhibitor glecaprevir. (See <a class="local">'Glecaprevir-pibrentasvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Velpatasvir</strong> – a pangenotypic NS5A inhibitor velpatasvir that is only available as a fixed-dose combination with the NS5B inhibitor <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>. (See <a class="local">'Sofosbuvir-velpatasvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ledipasvir</strong> – the first NS5A inhibitor to be available in the United States. It is available as part of a fixed-dose combination with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>. (See <a class="local">'Ledipasvir-sofosbuvir'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daclatasvir</strong> – an NS5A inhibitor that is available as a single drug and is used in combination with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>. (See <a class="local">'Daclatasvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elbasvir</strong> – an NS5A inhibitor that is only available as a fixed-dose combination with the protease inhibitor grazoprevir. (See <a class="local">'Elbasvir-grazoprevir'</a> below.)</p><p></p><p>Ravidasvir is an NS5A inhibitor with limited availability, mainly in resource-limited settings; it is used in combination with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> [<a href="#rid6">6</a>].</p><p>The NS5A protein plays a role in both viral replication and the assembly of the hepatitis C virus (HCV)<sup> </sup>[<a href="#rid7">7,8</a>]. However, the precise molecular mechanisms by which NS5A accomplishes these functions are uncertain. Thus, the exact mechanism of action of HCV NS5A inhibitors is unclear.</p><p>As a class, agents that inhibit NS5A are generally quite potent and are effective across all genotypes, but they have a low barrier to resistance and variable toxicity profiles  (<a class="graphic graphic_table graphicRef93884" href="/z/d/graphic/93884.html" rel="external">table 1</a>). NS5A inhibitors have been shown to significantly reduce HCV RNA levels and enhance sustained virologic response (SVR) when given in conjunction with peginterferon and <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a><sup> </sup>[<a href="#rid9">9</a>]. They also result in very high SVR rates among patients with genotype 1 infection when given in combination with other direct-acting antivirals with or without ribavirin [<a href="#rid10">10,11</a>]. </p><p class="headingAnchor" id="H1225365836"><span class="h2">NS5B RNA-dependent RNA polymerase inhibitors</span><span class="headingEndMark"> — </span>Contemporary NS5B inhibitors include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sofosbuvir</strong> – The first NS5B inhibitor to be available in the United States; it is a nucleotide polymerase inhibitor, specifically. It is used in combination with various other antiviral agents and is available as a single drug as well as in fixed drug combinations. (See <a class="local">'Sofosbuvir'</a> below and <a class="local">'Sofosbuvir-velpatasvir'</a> below and <a class="local">'Ledipasvir-sofosbuvir'</a> below and <a class="local">'Sofosbuvir-velpatasvir-voxilaprevir'</a> below.)</p><p></p><p>NS5B is an RNA-dependent RNA polymerase involved in post-translational processing that is necessary for replication of HCV. The enzyme has a catalytic site for nucleoside binding and at least four other sites at which a non-nucleoside compound can bind and cause allosteric alteration. The enzyme’s structure is highly conserved across all HCV genotypes, giving agents that inhibit NS5B efficacy against all six genotypes<sup> </sup>[<a href="#rid3">3</a>].</p><p>There are two classes of polymerase inhibitors: nucleoside/ nucleotide analogues (NPIs) and non-nucleoside analogues (NNPIs). The NPIs target the catalytic site of NS5B and result in chain termination, while NNPIs act as allosteric inhibitors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nucleot(s)ide polymerase inhibitors (NPIs)</strong> – Nucleotide inhibitors are activated within the hepatocyte through phosphorylation to nucleoside triphosphate, which competes with nucleotides, resulting in chain termination during RNA replication of the viral genome. </p><p></p><p class="bulletIndent1">As a class, NPIs have moderate to high efficacy across all six genotypes, with equal efficacy among subtypes 1a and 1b and have a very high barrier to resistance  (<a class="graphic graphic_table graphicRef93884" href="/z/d/graphic/93884.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">Another potential advantage of NPIs is that the NS5B active site is relatively intolerant to amino acid substitutions. As a result, active site NS5B mutations that confer resistance to NPIs are more likely to also impair RNA polymerase activity compared with mutations in NNPI allosteric binding pockets, thus rendering the mutant virus less "fit" compared with wild-type virus. </p><p></p><p class="bulletIndent1">However, the drug class as a whole has been plagued with toxicity problems, limiting the number of drugs that have completed late development.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-nucleoside polymerase inhibitors (NNPIs)</strong> – The four allosteric sites that act as targets for NNPIs are thumb domains 1 and 2 and palm domains 1 and 2. As a class, NNPIs are less potent, are more genotype specific (all NNPIs in clinical development have been optimized for genotype 1), have a low to moderate barrier to resistance, and have variable toxicity profiles<sup> </sup>[<a href="#rid12">12</a>].<sup> </sup>Consequently, this class of drug has been studied primarily as an adjunct to more potent compounds with higher barriers to resistance. See table for a summary of advantages and disadvantages of the four classes of drugs  (<a class="graphic graphic_table graphicRef93884" href="/z/d/graphic/93884.html" rel="external">table 1</a>). </p><p></p><p class="headingAnchor" id="H1509303515"><span class="h1">FIXED-DOSE COMBINATION AGENTS</span></p><p class="headingAnchor" id="H633525478"><span class="h2">Glecaprevir-pibrentasvir</span><span class="headingEndMark"> — </span>The NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir are coformulated in a single tablet [<a href="#rid13">13</a>]. The regimen is pangenotypic and has a high barrier to resistance. The clinical use of this regimen is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – The combination tablet consists of 100 mg glecaprevir and 40 mg pibrentasvir. The daily dose consists of three tablets taken at the same time, administered with food.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> can be used in patients with any degree of renal impairment, including those on dialysis, without the need for dose modifications. The regimen is contraindicated in patients with decompensated (Child-Pugh class B or C) cirrhosis because of a risk of worsening liver function or liver failure. In contrast, it is generally safe among patients with compensated (Child-Pugh class A) cirrhosis despite a two-fold increase in glecaprevir levels in such patients [<a href="#rid14">14</a>]. Nevertheless, it is important to ensure that the liver disease is not more advanced. (See <a class="local">'Protease inhibitors and hepatic decompensation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> is well tolerated. In an analysis of pooled data from multiple clinical trials, including over 2000 patients with chronic HCV infection who received glecaprevir-pibrentasvir, most adverse effects were mild, with headache and fatigue the most common complaints [<a href="#rid15">15</a>]. Less than 0.5 percent of patients discontinued therapy because of adverse effects. Elevations in aminotransferase or bilirubin levels were rare and not clearly related to the drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Glecaprevir and pibrentasvir are substrates and inhibitors of P-gp, breast cancer resistance protein (BCRP), and organic anion transporting polypeptide (OATP) 1B1/3. Coadministration is thus contraindicated with <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. Coadministration is not recommended with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, ethinyl estradiol-containing medications (such as oral contraceptive agents), St. John's wort, <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a>, lopinavir, <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, and certain statins (<a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, and <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>). </p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Virologic failure with <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> in patients without prior NS3 or NS5A inhibitor exposure is rare but has been associated with the emergence of various genotype-dependent substitutions in both NS3 and NS5A proteins [<a href="#rid16">16</a>]. However, among such patients, preexisting substitutions in the NS3 and NS5A proteins were not associated with treatment failure, except in treatment-experienced genotype 3-infected patients who received only 12 weeks of therapy.</p><p></p><p class="bulletIndent1">Among patients with prior NS3 or NS5A inhibitor exposure, preexisting substitutions in either NS3 or NS5A proteins were not associated with treatment failure [<a href="#rid17">17</a>]. However, when both NS3 and NS5A substitutions were present, seen only inpatients who have prior exposure to both NS3 and NS5A inhibitors, sustained virologic response (SVR) rates were compromised. <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> should not be used in this small group of patients. (See  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults", section on 'Relapse after sofosbuvir-velpatasvir (or other sofosbuvir-NS5A combination)'</a>.)</p><p></p><p class="headingAnchor" id="H1397087526"><span class="h2">Sofosbuvir-velpatasvir</span><span class="headingEndMark"> — </span>The pangenotypic NS5A inhibitor velpatasvir and the NS5B inhibitor <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> are coformulated in a single tablet. The clinical use of this regimen, which is effective against all genotypes, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – The combination tablet consists of 100 mg velpatasvir and 400 mg <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and is administered once daily with or without food. </p><p></p><p class="bulletIndent1">No dose adjustment is warranted for any degree of renal impairment, including patients requiring dialysis or in the setting of moderate (Child Pugh Class B) or severe (Child Pugh class C) hepatic impairment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The combination <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> is well tolerated. In an analysis of three trials of sofosbuvir-velpatasvir, adverse effects were common but occurred at similar rates and severity as among patients who received placebo [<a href="#rid18">18</a>]. The most common complaints were headache, fatigue, nausea, nasopharyngitis, and insomnia. Bradycardia is a rare but serious potential adverse effect associated with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, usually when used with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. (See <a class="local">'Sofosbuvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Velpatasvir, like <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, is a substrate of the P-glycoprotein (P-gp) drug transporter, so drugs that are potent intestinal P-gp inducers may decrease velpatasvir levels. Thus, coadministration of <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> is not recommended with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a>, St. John's wort, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, or <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">tipranavir</a>/<a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>. Coadministration is also not recommended with <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, which decreases the levels of velpatasvir. In addition, as an inhibitor of P-gp, velpatasvir may increase absorption of P-gp substrates. </p><p></p><p class="bulletIndent1">Increased gastric pH levels decrease absorption of velpatasvir; thus coadministration with proton pump inhibitors is ideally avoided. If a proton pump inhibitor is necessary, they can be coadministered, but it is important to follow the manufacturer's instructions: <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> should be administered with food and taken four hours prior to <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> 20 mg (other proton pump inhibitors have not been studied) [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1">Any drugs that should not be used with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> (such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>) should also not be used with <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> (see <a class="local">'Sofosbuvir'</a> below). For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Virologic failure in with <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> has been associated with emergence of the Y93N/H mutation in the NS5A gene in genotypes 1 and 3 virus [<a href="#rid20">20,21</a>]. In patients with genotype 3 infection, the presence of preexisting resistance-associated substitutions (in particular Y93H) appears to be associated with a higher likelihood of relapse, although even those with resistance-associated substitutions achieve high SVR rates (88 versus 97 percent in those without) [<a href="#rid20">20</a>]. No virologic failures were documented in the initial trials of sofosbuvir-velpatasvir in other genotypes. Mutational analysis testing for NS5A mutations are commercially available from LabCorp and Quest Labs.</p><p></p><p class="bulletIndent1">Polymorphisms associated with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> exposure are discussed elsewhere. (See <a class="local">'Sofosbuvir'</a> below.)</p><p></p><p class="headingAnchor" id="H3766320155"><span class="h2">Ledipasvir-sofosbuvir</span><span class="headingEndMark"> — </span>The NS5A inhibitor ledipasvir and the nucleotide polymerase (NS5B) inhibitor <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> are coformulated in a single tablet. This regimen is administered with or without weight-based <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, depending on the patient population. The clinical use of this regimen is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults", section on 'Alternative regimens'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – The combination tablet consists of 90 mg ledipasvir and 400 mg <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and is administered once daily with or without food. </p><p></p><p class="bulletIndent1">No dose adjustment is warranted for renal insufficiency or in the setting of moderate (Child Pugh Class B) or severe (Child Pugh class C) hepatic impairment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The combination of ledipasvir and <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> is well tolerated. Although the majority of patients in trials of <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> reported adverse effects of any kind, the vast majority were mild or moderate. The most common adverse effects reported are fatigue, headache, nausea, and insomnia. Bradycardia is a rare but serious potential adverse effect associated with sofosbuvir, usually when used with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. (See <a class="local">'Sofosbuvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Ledipasvir, like <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, is a substrate of the P-glycoprotein (P-gp) drug transporter, so drugs that are potent intestinal P-gp inducers may decrease ledipasvir levels. Thus, coadministration of <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> is not recommended with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a>, St. John’s wort, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, or <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">tipranavir</a>/<a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>. In addition, ledipasvir is an inhibitor of P-gp and may increase absorption of P-gp substrates. </p><p></p><p class="bulletIndent1">Increased gastric pH levels may decrease absorption of ledipasvir. Acid suppressing agents can be coadministered if necessary, but low doses or spaced out administration should be used. </p><p></p><p class="bulletIndent1">Any drugs that should not be used with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> (such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>) should also not be used with <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> (see <a class="local">'Sofosbuvir'</a> below). Clinical management of interactions with antiretroviral agents are discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/3701.html" rel="external">"Treatment of chronic hepatitis C virus infection in the patient with HIV", section on 'Ledipasvir-sofosbuvir'</a>). For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Virologic failure with <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> has been associated with several NS5A inhibitor mutations that reduce susceptibility to ledipasvir, most commonly Q30R, Y93H/N, and L31M in subtype 1a virus and Y93H in subtype 1b virus [<a href="#rid22">22,23</a>]. Although approximately 20 percent of genotype 1 viruses harbor polymorphisms that confer reduced susceptibility to ledipasvir, such preexisting resistance-associated polymorphisms did not appear to affect efficacy of ledipasvir-sofosbuvir in treatment-naïve patients. Further data are needed, but the presence of NS5A mutations does not require adjustment of duration or dosing, even though it may attenuate efficacy in treatment-experienced patients treated for 12 weeks. Mutational analysis testing for NS5A mutations are now commercially available from LabCorp and Quest Labs. </p><p></p><p class="bulletIndent1">Polymorphisms associated with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> exposure are discussed elsewhere. (See <a class="local">'Sofosbuvir'</a> below.) </p><p></p><p class="headingAnchor" id="H2932457999"><span class="h2">Sofosbuvir-velpatasvir-voxilaprevir</span><span class="headingEndMark"> — </span>This combination adds the NS3/4A inhibitor voxilaprevir to the NS5B inhibitor <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and the NS5A inhibitor velpatasvir. This regimen is pangenotypic and mainly reserved for patients who have prior failure on DAA (and predominantly NS5A inhibitor-containing) regimens. The clinical use of this regimen is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – The combination tablet consists of 400 mg <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, 100 mg velpatasvir, and 100 mg voxilaprevir, and is administered once daily with food. </p><p></p><p class="bulletIndent1">No dose adjustment is warranted for renal insufficiency (including patients on dialysis) or in the setting of mild (Child Pugh Class A) hepatic impairment. This regimen is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to higher exposures of voxilaprevir seen in these patients. (See <a class="local">'Protease inhibitors and hepatic decompensation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The combination is well tolerated. In trials, &lt;1 percent of participants discontinued a 12-week regimen for adverse events [<a href="#rid24">24</a>]. The most common adverse events are headache, fatigue, diarrhea, and nausea. Bradycardia is a rare but serious potential adverse effect associated with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, usually when used with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. (See <a class="local">'Sofosbuvir'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – The same drug interactions with <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> apply to <a class="drug drug_general" data-topicid="114088" href="/z/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a> (see <a class="local">'Sofosbuvir-velpatasvir'</a> above). Additionally, coadministration is contraindicated with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and is not recommended with <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a>, lopinavir, certain statins (<a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> and <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>), and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. </p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Although virologic failure with <a class="drug drug_general" data-topicid="114088" href="/z/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a> has been associated with emergence of substitutions in the NS3 and NS5A proteins, preexisting substitutions in these proteins or in the NS5B protein are not associated with lower SVR rates [<a href="#rid24">24</a>]. No data are available to guide management of patients who have failed this regimen in the setting of prior NS5A or NS3 resistance-associated substitutions (7 of 445 patients in two trials).</p><p></p><p class="headingAnchor" id="H413203164"><span class="h2">Elbasvir-grazoprevir</span><span class="headingEndMark"> — </span>Elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor with a high barrier of resistance, are coformulated in a single tablet [<a href="#rid13">13</a>]. This regimen is effective against genotypes 1 and 4 infection and is administered with or without weight-based <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, depending on certain patient characteristics. <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">Elbasvir-grazoprevir</a> is no longer frequently used in the United States. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – The combination tablet consists of 50 mg elbasvir and 100 mg grazoprevir and is administered once daily with or without food. </p><p></p><p class="bulletIndent1">Prior to administration of <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a>, patients with genotype 1a infection should be tested for the presence of NS5A resistance associated substitutions (RASs) and all patients should have documentation of baseline aminotransferases. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">Elbasvir-grazoprevir</a> can be used in patients with any degree of renal impairment, including those on dialysis, without the need for dose modifications. The regimen is contraindicated in patients with Child-Pugh class B or C cirrhosis. (See <a class="local">'Protease inhibitors and hepatic decompensation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">Elbasvir-grazoprevir</a> is well tolerated. In large trials, the most common adverse events were headache, fatigue, and nausea [<a href="#rid25">25,26</a>]. Serious adverse events occurred rarely and at the same rate as with placebo. Approximately 1 percent of patients developed late aminotransferase elevations greater than five times the upper limit of normal (ULN) without associated bilirubin increases that resolved once the regimen was stopped. Aminotransferase monitoring at baseline and at week 8 of therapy (and at week 12, if the total duration is 16 weeks) is recommended [<a href="#rid13">13</a>]. The regimen should be discontinued if aminotransferase elevations are accompanied by other signs or symptoms of hepatic injury (eg, jaundice, increasing bilirubin or INR). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Elbasvir and grazoprevir are primarily metabolized through CYP3A metabolism and should not be given with moderate and strong inducers or strong inhibitors of this enzyme  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 2</a>). Grazoprevir is a substrate of OATP1B1/3 transporters and should not be given with drugs that inhibit this enzyme. Coadministration is thus contraindicated with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, St. John's wort, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and certain antiretroviral agents (protease inhibitors and <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>). Coadministration is not recommended with <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">etravirine</a>, <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a>, and <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a>.</p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Preexisting polymorphisms in the NS5A protein that are associated with resistance to elbasvir and lower SVR rates with <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> in genotype 1a patients are at positions M28, Q30, L31, and Y93 [<a href="#rid25">25,27</a>]. Approximately 11 percent of genotype 1a viruses are estimated to harbor one of these polymorphisms. Patients with genotype 1a virus should be tested these polymorphisms prior to using elbasvir-grazoprevir; in patients with one of these present, SVR rates can be improved by adding weight-based <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> and extending the treatment course. The presence of these polymorphisms do not appear to significantly affect SVR rates with genotype 1b virus. Mutational analysis testing for NS5A mutations is commercially available from LabCorp and Quest Labs. </p><p></p><p class="bulletIndent1">Polymorphisms in the NS3 protein, including the Q80L polymorphism in genotype 1a virus, do not appear to impact treatment response to <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a>. NS3/4 polymorphisms that emerge after failure on the elbasvir-grazoprevir regimen tend to disappear after 100 to 200 days, whereas emergent NS5A polymorphisms tend to persist for as long as the patients are followed (beyond 900 days) [<a href="#rid28">28</a>]. This suggests that salvage regimens will be necessary for the NS5A-resistant polymorphisms only. </p><p></p><p class="headingAnchor" id="H217260907"><span class="h1">SINGLE-DRUG AGENTS</span></p><p class="headingAnchor" id="H212554856"><span class="h2">Sofosbuvir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">Sofosbuvir</a> is the first NS5B nucleoside polymerase inhibitor to be available in the United States.<sup> </sup>Sofosbuvir is used in various combinations with other antivirals for different indications. It is usually used as part of a fixed-dose combination, but is also available as a single drug, usually used in combination with daclatasvir. (See <a class="local">'Fixed-dose combination agents'</a> above and <a class="local">'Daclatasvir'</a> below.)</p><p>Selection of sofosbuvir-containing regimens for treatment of chronic HCV is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">Sofosbuvir</a> is easily administered:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">Sofosbuvir</a> 400 mg orally once daily with or without food<sup> </sup>(available as 400 mg tablet)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">Sofosbuvir</a> should not be used without other antiviral agents, and the dose of sofosbuvir should not be decreased. Although renal clearance is the major form of elimination of sofosbuvir and exposure is increased in patients with severe renal impairment, including those on dialysis, studies suggest safe use without dose adjustment in this population. In the United States, the drug is FDA approved for use in patients with chronic kidney disease classes 4 and 5. (See  <a class="medical medical_review" href="/z/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment", section on 'Direct-acting antivirals'</a>.)</p><p></p><p class="bulletIndent1">When used in patients with cirrhosis, no dose adjustment has been needed in patients with moderate (Child Pugh Class B) or severe (Child Pugh class C) hepatic impairment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">Sofosbuvir</a> is well tolerated with no significant side effects beyond what is seen with peginterferon and <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>. In clinical trials, the most commonly reported adverse effects of sofosbuvir and ribavirin, with or without peginterferon, are fatigue, headache, nausea, insomnia, and anemia [<a href="#rid29">29-31</a>]. Rare cases of symptomatic bradycardia have been reported following the initiation of sofosbuvir-containing regimens; most, but not all, have been in the context of concomitant use with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Drug interactions with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> are substantially less than those observed with the HCV protease inhibitors. Sofosbuvir is a substrate of the P-glycoprotein (P-gp) drug transporter, so drugs that are potent intestinal P-gp inducers may decrease sofosbuvir levels. Thus, coadministration of sofosbuvir is not recommended with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a>, St. John’s wort, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, or <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">tipranavir</a>/<a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>. Coadministration of sofosbuvir and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is also not recommended because of reports of symptomatic bradycardia and a fatal cardiac arrest among patients taking amiodarone who initiated a sofosbuvir-containing regimen [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Resistant polymorphisms within the NS5B polymerase have been reported with in vitro exposure to <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, although their clinical significance is uncertain. These polymorphisms include S282T, L159F, and E341D. In particular, the S282T polymorphism is associated with reduced susceptibility to sofosbuvir [<a href="#rid36">36</a>]. However, this mutation has only been clinically identified in one patient who experienced virologic relapse in trials of sofosbuvir-containing regimens [<a href="#rid22">22,37</a>]. Other substitutions have been identified in patients who were exposed to up to 48 weeks of sofosbuvir plus <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> while awaiting liver transplantation, but the clinical significance of these substitutions is unknown.</p><p></p><p class="headingAnchor" id="H1537847397"><span class="h2">Daclatasvir</span><span class="headingEndMark"> — </span>Daclatasvir is an NS5A inhibitor that is used mainly in combination with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>. Daclatasvir is now infrequently used in the United States but is used in other parts of the world. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – Daclatasvir is given as a 60 mg oral dose once daily with or without food. Daclatasvir is only used in combination with other DAA agents. </p><p></p><p class="bulletIndent1">No dose adjustments are required for renal or hepatic impairment. Dose modifications are warranted when used with certain other medications, as below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Daclatasvir is generally well tolerated. In clinical trials of daclatasvir-containing regimens, headache, fatigue, and nausea were the most commonly reported adverse effects [<a href="#rid11">11,38</a>]. These were mild to moderate in severity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Daclatasvir is primarily metabolized through CYP3A metabolism and should not be given with strong inducers of this enzyme. Coadministration of daclatasvir is thus not recommended with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, and St. John's wort. A dose reduction to 30 mg once daily is recommended when daclatasvir is used with strong CYP3A inhibitors (such as ritonavir-boosted <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a>, some azole agents, and <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>). A dose increase to 90 mg once daily is recommended when daclatasvir is used with moderate CYP3A inducers (such as <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">etravirine</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>). </p><p></p><p class="bulletIndent1">Daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP). Dose adjustments of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> may be warranted when used with daclatasvir. </p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. Interactions with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> should also be considered when daclatasvir is used in combination with sofosbuvir. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Polymorphisms in the NS5A protein that are associated with resistance to daclatasvir in vitro include polymorphisms at M28, A30, L31, and Y93; mutations at the Y93 site appear to be the most clinically relevant. A baseline Y93H polymorphism was detected in 13 of 148 genotype 3-infected patients in a clinical trial of daclatasvir plus <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and was associated with lower sustained virologic response (SVR) rates [<a href="#rid38">38</a>]. Among the 10 patients who had virologic failure and did not have a Y93H polymorphism at baseline, Y93H emerged in 9 of them. Other polymorphisms were not associated with worse clinical response. Mutational analysis testing for NS5A mutations is commercially available from LabCorp and Quest Labs. </p><p></p><p class="headingAnchor" id="H1256557961"><span class="h2">Simeprevir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">Simeprevir</a> was the first available second-generation protease inhibitor [<a href="#rid39">39</a>]. Simeprevir is not used in the United States but may be used in other parts of the world. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and pharmacology</strong> – <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">Simeprevir</a> is easily administered:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">Simeprevir</a> 150 mg orally once daily with food (available in 150 mg capsules)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">Simeprevir</a> should not be used without other antiviral agents, and the dose of simeprevir should not be decreased. No dose adjustment is required in the setting of renal impairment. The elimination of simeprevir is by the liver [<a href="#rid40">40</a>]. Simeprevir cannot be recommended in patients with moderate (Child Pugh Class B) or severe (Child Pugh class C) hepatic impairment because of increases in exposure of two- to fivefold (see <a class="local">'Protease inhibitors and hepatic decompensation'</a> below). In addition, higher exposure to simeprevir was reported in patients of Eastern Asian ancestry, and simeprevir should be used with caution in this group [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In general, <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a> is well tolerated. Treatment discontinuation for adverse effects appears infrequent [<a href="#rid42">42,43</a>]. Photosensitivity and rash were reported in the simeprevir program with some serious reactions requiring hospitalization. Patients should be cautioned about this risk and instructed to use sun protective measures and limit sun exposure. If a severe rash or photosensitivity reaction occurs, simeprevir should be discontinued.</p><p></p><p class="bulletIndent1">In addition, transient, mild elevations in bilirubin have been observed with <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a> due to decreased bilirubin elimination related to inhibition of the hepatic transporters OATP1B1 and MRP2, but no pattern to suggest liver toxicity has been observed. Pruritus and nausea have also been associated with simeprevir use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">Simeprevir</a> is oxidatively metabolized by CYP3A subfamily, which consists mainly of hepatic and intestinal CYP3A4 metabolism [<a href="#rid44">44</a>]. Therefore, coadministered drugs that are significant inducers or inhibitors of CYP3A4 are expected to alter concentrations of simeprevir  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 2</a>). This effect on simeprevir has been confirmed for several CYP3A4 inhibitors and inducers [<a href="#rid40">40</a>]. Simeprevir, in turn, may affect the levels of other agents. As an example, simeprevir also inhibits OATP1B1/3, and substrates of OATP1B1/3 such as <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> are increased.</p><p></p><p class="bulletIndent1">Among the HIV antiretrovirals, <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a> is not recommended with <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, HIV protease inhibitors, and the non-nucleoside reverse transcriptase inhibitors <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>. Simeprevir can be administered without dose adjustments with <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">rilpivirine</a>, <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">maraviroc</a>, and all nucleos(t)ide reverse transcriptase inhibitors, including tenofovir. </p><p></p><p class="bulletIndent1">In post-liver transplant patients with HCV infection, coadministration of <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> resulted in significantly elevated simeprevir levels, so it is not recommended [<a href="#rid41">41</a>]. Simeprevir can be safely administered with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. </p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> – Many of the second-generation protease inhibitors are macrocyclic molecules, which have been shown to be generally more potent. Additionally, depending on the location of the macrocycle, they are able to retain activity against resistant variants. Common wild-type and drug-resistant polymorphisms of the NS3 protein include Q80K, R155K, V36M/R155K, A156T, and D168A [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">Several mutations in the NS3/4A protease are associated with reduced susceptibility to <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a>. One of the most prevalent and clinically relevant mutations is the substitution Q80K. Among patients in clinical trials of simeprevir plus peginterferon and <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, this polymorphism was present at baseline in 30 percent of patients with genotype 1a and was associated with a lower SVR rate (58 versus 84 percent if the Q80K was not present) [<a href="#rid46">46</a>]. Preliminary data suggest that the Q80K mutation does not substantially impact response rates to the combination of simeprevir and <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> [<a href="#rid47">47</a>]. In the United States, testing for this polymorphism is available at LabCorp.</p><p></p><p class="bulletIndent1">Resistance mutations that emerge during unsuccessful treatment with first-generation protease inhibitors, such as R155K and A156T/V, are also associated with decreased in vitro susceptibility to <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a> and are expected to impact clinical response to simeprevir [<a href="#rid40">40</a>]. </p><p></p><p class="headingAnchor" id="H3984630677"><span class="h1">CLASS ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Overall, direct-acting antiviral (DAA) regimens are extremely well tolerated, with only mild to moderate side effects. In a retrospective study of over 30,000 patients with HCV infection seen at three health systems in the United States between 2012 and 2017, DAA exposure was associated with a lower rate of death (11 versus 34 events per 1000 person-years) and various other severe adverse events, including multiple organ failure, hepatic decompensation, liver cancer, acute myocardial infarction, and stroke [<a href="#rid48">48</a>]. </p><p>Nevertheless, rare severe adverse events can occur. </p><p class="headingAnchor" id="H3429824350"><span class="h2">HBV reactivation</span><span class="headingEndMark"> — </span>As an example, reactivation of hepatitis B virus (HBV) infection, in some cases with fulminant liver failure, has been described during DAA treatment of (HCV) infection [<a href="#rid49">49</a>]. A subsequent review identified 524 cases of liver failure reported to the US Food and Drug Administration (FDA) over the course of one year, with an estimated 250,000 individuals treated over a similar time frame [<a href="#rid50">50</a>]. Reactivation may be due to diminished hepatic interferon response following HCV clearance [<a href="#rid51">51</a>]. However, it is unclear what proportion of these cases represent HBV reactivation or complications in patients with existing advanced liver disease (including inappropriate use of protease inhibitors in patients with decompensated disease), situations in which the risk of liver failure is higher than the general population. Patients should understand that this risk is overall very low.</p><p>Monitoring for and managing HBV reactivation in the setting of HCV treatment is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring for toxicity'</a> and  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'HBV coinfection'</a>.)</p><p class="headingAnchor" id="H769897151"><span class="h2">Protease inhibitors and hepatic decompensation</span><span class="headingEndMark"> — </span>Cases of hepatic decompensation or failure, including events with fatal outcomes, have been reported in patients who received HCV protease inhibitor-containing regimens [<a href="#rid52">52</a>]. Many of the cases were in patients with decompensated (Child class B or C) cirrhosis, among whom these agents are not recommended. However, some of the cases were in patients who were labeled as having no cirrhosis or compensated (Child class A) cirrhosis. Details of these cases are lacking, and many of those without a diagnosis of decompensated cirrhosis had evidence of more advanced liver impairment, such as decreased platelet levels or increased portal pressure. Some also had other potential contributors to liver disease, such as liver cancer and alcohol use disorder. Pending further data, we check endoscopy in patients with platelet counts &lt;150,000/microL or with a transient elastography score &gt;20 kPa prior to antiviral treatment and avoid protease inhibitor-containing regimens in those with evidence of any esophageal varices. </p><p class="headingAnchor" id="H873811315"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113060.html" rel="external">"Society guideline links: Hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H1818005026"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral targets</strong> – The main targets of the direct-acting antiviral (DAA) agents are the HCV-encoded proteins that are vital to the replication of the virus  (<a class="graphic graphic_figure graphicRef94365" href="/z/d/graphic/94365.html" rel="external">figure 1</a>). Available DAAs are inhibitors of the NS3/4A protease, the NS5A protein, or the NS5B polymerase  (<a class="graphic graphic_table graphicRef93884" href="/z/d/graphic/93884.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Viral life cycle and replication overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Protease inhibitors</strong> – Glecaprevir, voxilaprevir, and grazoprevir are HCV protease inhibitors that offer several benefits over earlier protease inhibitors (such as telaprevir and boceprevir), including fewer drug-drug interactions, improved dosing schedules, and less frequent and less severe side effects. Nevertheless, few significant drug-drug interactions may limit their use. (See <a class="local">'NS3/4A protease inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NS5A inhibitors</strong> – Agents that inhibit NS5A are generally quite potent and are effective across genotypes, but they have a low barrier to resistance and variable toxicity profiles. Velpatasvir, ledipasvir, daclatasvir, and elbasvir are all well-tolerated NS5A inhibitors. (See <a class="local">'NS5A inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NS5B inhibitors</strong> – The NS5B protein is an RNA-dependent RNA polymerase; inhibitors are either nucleoside or non-nucleoside polymerase inhibitors. <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">Sofosbuvir</a> is a nucleoside polymerase inhibitor with high potency across all six genotypes, a very high barrier to resistance, and few expected drug-drug interactions. Non-nucleoside polymerase inhibitors have a lower threshold for resistance than other classes; no clinically available antiviral agent is in this class. (See <a class="local">'NS5B RNA-dependent RNA polymerase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fixed-dose combination regimens</strong> – Several DAAs are only available as part of fixed-dose combinations. These are <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a>, <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>, <a class="drug drug_general" data-topicid="114088" href="/z/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a>, and <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a>, the latter of which is administered with dasabuvir for certain genotypes. (See <a class="local">'Fixed-dose combination agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class adverse effects</strong> – Overall, DAAs are safe and well tolerated, although there have been sporadic reports of worsening liver disease in patients with hepatitis B virus coinfection and in patients with decompensated cirrhosis who received protease inhibitor-containing regimens (which are contraindicated). (See <a class="local">'Class adverse effects'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19:449.</a></li><li><a class="nounderline abstract_t">Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19:837.</a></li><li><a class="nounderline abstract_t">Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3:191.</a></li><li class="breakAll">US Food and Drug Administration. Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm255413. (Accessed on August 1, 2013).</li><li class="breakAll">US Food and Drug Administration. Approval of Incivek (telaprevir) a direct-acting antiviral (DAA) to treat hepatitis C virus (HCV) infection. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=201917.</li><li><a class="nounderline abstract_t">Andrieux-Meyer I, Tan SS, Thanprasertsuk S, et al. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol 2021; 6:448.</a></li><li><a class="nounderline abstract_t">Evans MJ, Rice CM, Goff SP. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A 2004; 101:13038.</a></li><li><a class="nounderline abstract_t">Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4:e1000032.</a></li><li><a class="nounderline abstract_t">Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96.</a></li><li><a class="nounderline abstract_t">Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879.</a></li><li><a class="nounderline abstract_t">Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211.</a></li><li><a class="nounderline abstract_t">Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014; 95:78.</a></li><li class="breakAll">Zepatier (elbasvir and grazoprevir). US FDA approved product information; Whitehouse Station, NJ: Merck and Co, Inc; January 2016. </li><li><a class="nounderline abstract_t">Gane E, Poordad F, Zadeikis N, et al. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis 2019; 69:1657.</a></li><li class="breakAll">Dufour JF, Zuckerman E, Zadeikis N, et al. Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6  Hepatitis C Virus Infection: An Integrated Analysis. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.</li><li class="breakAll">Krishnan P, Schnell G, Tripathi R, et al. Pooled resistance analysis in HCV genotype 1-6 infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.</li><li class="breakAll">Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, Part 2: Glecaprevir/pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.</li><li class="breakAll">Jacobson IM, Brau N, Bourgeois S, et al. The tolerability of sofosbuvir/velpatasvir for 12 Weeks in &gt;1000 patients treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies: An integrated safety analysis. Presented at the 51st Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 13-17, 2016.
</li><li class="breakAll">Epclusa (sofosbuvir and velpatasvir). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov.</li><li><a class="nounderline abstract_t">Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373:2608.</a></li><li><a class="nounderline abstract_t">Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.</a></li><li class="breakAll">Harvoni (ledipasvir-sofosbuvir). US FDA approved product information. National Library of Medicine.</li><li><a class="nounderline abstract_t">Wyles D, Dvory-Sobol H, Svarovskaia ES, et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol 2017; 66:703.</a></li><li><a class="nounderline abstract_t">Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017; 376:2134.</a></li><li><a class="nounderline abstract_t">Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015; 163:1.</a></li><li><a class="nounderline abstract_t">Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1075.</a></li><li class="breakAll">Thompson A, Zeuzem S, Rockstroh J, Kwo P, et al. The combination of elbasvir and grazoprevir ± RBV is highly effective for the treatment of GT1a-infected patients. Presented at the American Association for the Study of Liver Diseases Liver Meeting, San Francisco CA, November 13-17, 2015.</li><li><a class="nounderline abstract_t">Lahser F, Galloway A, Hwang P, et al. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated variants (RAVs) after treatment with grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection. Hepatology 2016; 64:32A.</a></li><li><a class="nounderline abstract_t">Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878.</a></li><li><a class="nounderline abstract_t">Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13:401.</a></li><li><a class="nounderline abstract_t">Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100.</a></li><li><a class="nounderline abstract_t">Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med 2015; 373:1886.</a></li><li><a class="nounderline abstract_t">Brainard DM, McHutchison JG. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med 2015; 373:1888.</a></li><li class="breakAll">FDA Hepatitis Update - Important safety information: Harvoni and Sovaldi. March 21, 2015. http://content.govdelivery.com/accounts/USFDA/bulletins/f97c71 (Accessed on March 30, 2015).</li><li><a class="nounderline abstract_t">Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149:1378.</a></li><li class="breakAll">Rajyaguru S, Xu S, Hebner C, et al. Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance associated variants selected by other classes of antiviral inhibitors. Presented at the 64th annual meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013. Abstract #1094.</li><li><a class="nounderline abstract_t">Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59:1666.</a></li><li><a class="nounderline abstract_t">Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127.</a></li><li class="breakAll">Prescribing Information for OLYSIOTM (simeprevir): Janssen Therapeutics, Division of Janssen Products, LP, Titusville NJ 08560. Issued November 2013.</li><li class="breakAll">Olysio (simeprevir). US FDA approved product information. National Library of Medicine. Available online at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1816fd68-0ed7-4a37-84bb-e298c5ab6e28 (Accessed on November 17, 2014).</li><li class="breakAll">US Food and Drug administration. Olysio prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdfa (Accessed on October 15, 2014).</li><li class="breakAll">Jacobson IM, Dore, GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Presented at the 48th annual meeting of the European Association for the Study of  the Liver, Amsterdam, The Netherlands, April 24-28, 2013. Abstract 1425.</li><li class="breakAll">Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Presented at the 48th annual meeting of the European Association for the Study of  the Liver, Amsterdam, The Netherlands, April 24-28, 2013. Abstract 1413.</li><li><a class="nounderline abstract_t">Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883.</a></li><li><a class="nounderline abstract_t">Ali A, Aydin C, Gildemeister R, et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol 2013; 8:1469.</a></li><li class="breakAll">Lenz O, Fevery B, Verbinnen T, et al. Resistance analyses of HCV isolates from patients treated with simeprevir in phase 2b/3 studies. Presented at the 64th annual meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013. Abstract #1101.</li><li><a class="nounderline abstract_t">Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756.</a></li><li><a class="nounderline abstract_t">McGlynn EA, Adams JL, Kramer J, et al. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open 2019; 2:e194765.</a></li><li class="breakAll">FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm (Accessed on October 05, 2016).</li><li class="breakAll">QuaterWatch: Monitoring FDA MedWatch Reports. Institute For Safe Medication Practices. January 25, 2017. http://www.ismp.org/quarterwatch/pdfs/2016Q2.pdf.</li><li><a class="nounderline abstract_t">Cheng X, Uchida T, Xia Y, et al. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest 2020; 130:3205.</a></li><li class="breakAll">FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. August 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and (Accessed on October 10, 2019).</li></ol></div><div id="topicVersionRevision">Topic 93242 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22676357" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23836234" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21180601" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New direct-acting antivirals in the development for hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21180601" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New direct-acting antivirals in the development for hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21180601" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New direct-acting antivirals in the development for hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33865507" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15326295" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18369478" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410884" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24720702" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24428467" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126682" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Novel therapeutic approaches for hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126682" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Novel therapeutic approaches for hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575258" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571066" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571066" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27923693" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28564569" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25909356" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467591" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467591" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated variants (RAVs) after treatment with grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607594" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sofosbuvir for previously untreated chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499158" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499440" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535533" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bradyarrhythmias Associated with Sofosbuvir Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535532" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bradyarrhythmias Associated with Sofosbuvir Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535532" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bradyarrhythmias Associated with Sofosbuvir Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26253303" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26253303" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266287" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124305" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594083" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594083" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078309" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31173117" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31173117" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31173117" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32163375" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
